The historical rank and industry rank for KPC Pharmaceuticals's Net Margin % or its related term are showing as below:
SHSE:600422'
s Net Margin % Range Over the Past 10 Years
Min: 2.03 Med: 5.78 Max: 7.98
Current: 2.03
SHSE:600422's Net Margin % is ranked worse than 60.97% of 953
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs SHSE:600422: 2.03
KPC Pharmaceuticals (SHSE:600422) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
KPC Pharmaceuticals Net Margin % Related Terms
KPC Pharmaceuticals Net Margin % Historical Data
* Premium members only.
The historical data trend for KPC Pharmaceuticals's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, KPC Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KPC Pharmaceuticals Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, KPC Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where KPC Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KPC Pharmaceuticals (SHSE:600422) has a Net Margin % of -16.96% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on KPC Pharmaceuticals and its competitors. Over the past decade, KPC Pharmaceuticals' Net Margin % has ranged from 2.03 to 7.98. According to the industry distribution chart, KPC Pharmaceuticals ranks #581 out of 953 companies in the Drug Manufacturers industry, placing it in the top 61%.
Is KPC Pharmaceuticals' Net Margin % too high?
KPC Pharmaceuticals' current Net Margin % is -16.96%. Over the past 10 years, this metric has ranged from a low of 2.03 to a high of 7.98. Based on the distribution chart, KPC Pharmaceuticals ranks #581 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, KPC Pharmaceuticals has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does KPC Pharmaceuticals' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, KPC Pharmaceuticals ranks #581 out of 953 companies for Net Margin %. This places KPC Pharmaceuticals in the lower half of its industry. The industry median Net Margin % is 5.69. Historically, KPC Pharmaceuticals' own Net Margin % has ranged from 2.03 to 7.98 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on KPC Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KPC Pharmaceuticals's current Net Margin % is -16.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KPC Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, KPC Pharmaceuticals (SHSE:600422) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥11.77, compared to a current price of ¥7.70 — trading 34.6% below its estimated fair value. The current Net Margin % is -16.96%. KPC Pharmaceuticals' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For KPC Pharmaceuticals (SHSE:600422), the current Net Margin % is -16.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KPC Pharmaceuticals (SHSE:600422) Overvalued in 2026?
Based on GuruFocus' analysis, KPC Pharmaceuticals stock appears to be undervalued.
The current stock price of ¥7.70 is trading 34.6% below its estimated GF Value™ of ¥11.77.
GuruFocus considers KPC Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for SHSE:600422:
Net Margin %: -16.96%
GF Value™: ¥11.77 vs. price of ¥7.70 (34.6% below fair value)
No single metric tells the full story. See the SHSE:600422 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
62GF Score
Get the complete analysis for SHSE:600422
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600422 has been successfully added to your 
